Day: 2026 年 2 月 11 日

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - February 11, 2026) - Casa Minerals Inc. (TSXV: CASA) (OTCQB: CASXF) (FSE: 0CM) (the "Company" or "Casa"), is pleased to announce closing of the final tranche of its previously announced non-brokered private placement (the "Offering"). The Company has closed a total of 2,635,000 units (each, a "Unit") at a price of $0.125 per unit for gross proceeds of up to $329,375.00 in this tranche, which would be a grand total of 7,552,000 units (each, a "Unit") for a gross proceed of $944,000 for the announced financing.Each Unit consists of one common share of the Company (a "Share") and one common share purchase warrant (each full warrant, a "Warrant"). Each of the 2,635,000 Warrants entitles the holder to acquire one additional share for a period of two years. The warrant exercise strike price is $0.15/share in the first three months and automatically converts to $0.20 per share then after for the remainder of the two years period.All issued Securities will be subject to a 4-month and one day hold-period, during which any resale or other transfer will be restricted in accordance with applicable securities laws.A Finder's Fees of $18,450 has been paid to registered financial institutions for this tranche.Net proceeds from the offering will be used for general administration, exploration and development activities on the Company's projects in Arizona, and British Columbia, Canada. The Company will continue to raise the remaining placement in the coming week.The completion of the private placement remains subject to approval of the TSX Venture Exchange.None of the securities issued in the Offering will be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act.Company is also pleased to announce that CASA has entered into a digital marketing agreement (the "BorsenBlick Agreement") with BorsenBlick, a European-based marketing agency, to support investor awareness and strengthen its brand visibility.Under the agreement, BorsenBlick will provide digital marketing and awareness services designed to support investor outreach, brand visibility, and public profile enhancement for two months at 80,500 Canadian Dollars per month. The Company retains the discretion to extend the campaign or renew the agreement upon completion of the initial program. Jan Kellett is the founder of BorsenBlick and can be reached at jan@snowbridge.link. Both BorsenBlick and its principals are arm's length to the Company and do not have any interest, direct or indirect, in the Company or its securities nor do they have any right to acquire such an interest.About Casa Minerals Inc.The Company is engaged in the acquisition, exploration and development of mineral properties located in Canada and the USA. Casa owns ninety percent (90%) interest in the Congress gold mine (Arizona, USA). Additionally, the Company owns a one hundred percent (100%) interest in the polymetallic Pitman (BC, Canada) and has an option to acquire a seventy-five percent (75%) interest in the Arsenault VMS Property (BC, Canada).On Behalf of Board of DirectorsFarshad Shirvani, M.Sc. GeologyPresident and CEOFor more information, please contact:Casa Minerals Inc.Farshad Shirvani, President & CEOPhone: (604) 678-9587Email: contact@casaminerals.comhttps://www.casaminerals.comNEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/283634 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Feb 11, 2026 - (ACN Newswire via SeaPRwire.com) – As the joint sponsor, overall coordinator, joint global coordinator, joint bookrunner and joint lead manager, Guotai Junan International Holdings Limited (“GTJAI”, stock code: 1788.HK), a company of Guotai Haitong Group, successfully assisted Axera Semiconductor Co., Ltd. (“Axera”, stock code: 600.HK) in its official listing on the Main Board of the Hong Kong Stock Exchange on February 10. This listing enriches the investment options in the Hong Kong stock market for edge AI inference system chips and demonstrates Guotai Haitong Group’s comprehensive strength in serving semiconductor technology companies.Axera is a provider of artificial intelligence (“AI”) inference systems-on-a-chip (“SoC”), delivering high-performance perception and computing platforms for edge and endpoint AI applications. It is building an advanced AI computing infrastructure to make artificial intelligence accessible to everyone. According to its prospectus, Axera is the largest provider of mid-to-high-end visual on-device AI inference chips in the world and ranks among the top five players in the global visual on-device AI Inference chip market, in terms of the shipments in 2024. Its Axera Proton AI-ISP is the world’s first AI-ISP technology commercialized at scale, marking a significant milestone in the computer vision industry. As of September 30, 2025, Axera had cumulatively delivered over 165 million SoC units since its inception. AXERA had independently developed and commercialized five generations of SoCs, spanning dozens of types, that have achieved large-scale production in visual on-device computing, smart vehicle and edge AI inference applications.The offer price is HK$28.20 per share, with a total of 104,915,200 H shares in the Global Offering and base proceeds from the offering of approximately HK$2,959 million. If the over-allotment option is fully exercised, the total proceeds are expected to reach approximately HK$3,402 million. Both the International Offering and the Hong Kong Offering were met with enthusiastic subscription, with the International Offering oversubscribed by approximately 6.8 times and the Hong Kong Offer oversubscribed by approximately 104.82 times. The offering successfully attracted cornerstone investors including WILL Semiconductor, Xin Ma Apparel, JSC Fund, NGS Super, Desay SV, Factorial Fund, Hel Ved Fund, Valliance, and Alphahill Capital. These cornerstone investors collectively subscribed to approximately HK$1,443 million worth of shares, accounting for about 48.76% of the total shares. This not only fully demonstrates the market’s recognition of AXERA’s business model and long-term development prospects, but also provides support for the stability of the post-listing stock price.The success of this project highlights GTJAI’s deep understanding of the artificial intelligence chip industry and its professional ability to serve high-tech industries. Moving forward, Guotai Haitong Group will continue to focus on the field of technological innovation, fully leverage its integrated domestic and international collaborative advantages, and rely on its full-chain financial services system to provide comprehensive empowerment—from capital operations to strategic resource integration—for more hard-tech enterprises. This will assist them in efficiently connecting with global capital markets and jointly exploring the new era of intelligence.About GTJAIGuotai Junan International (Stock Code: 1788.HK), a subsidiary of Guotai Haitong Group, is the market leader and first mover for internationalization of Chinese Securities Company as well as the first Chinese securities broker listed on the Main Board of The Hong Kong Stock Exchange through initial public offering. Based in Hong Kong with subsidiaries in Singapore, Vietnam and Macau, GTJAI’s business covers major markets around the world, offering high-quality and diversified comprehensive financial services for clients' overseas asset allocation. Core business includes wealth management, institutional investor services, corporate finance services, investment management and other business. GTJAI has been assigned “Baa2” and “BBB+” long term issuer rating from Moody and Standard & Poor respectively, as well as an MSCI ESG “A” rating, Wind ESG “A” rating and SynTao Green Finance “A” rating in ESG. Additionally, its S&P Global ESG score leads 81% of its global peers. The controlling shareholder, Guotai Haitong Securities (Stock Code: 601211.SH/ 2611.HK), is the comprehensive financial provider with a long-term, sustainable and overall leading position in the China’s capital markets. For more information about GTJAI, please visit https://www.gtjai.com. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月11日 - (亞太商訊 via SeaPRwire.com) - 2月10日,國泰海通集團下屬公司國泰君安國際控股有限公司（「國泰君安國際」或「公司」，股份代號：1788.HK）作為聯席保薦人、整體協調人、聯席全球協調人、聯席全球協調人、聯席帳簿管理人及聯席牽頭經辦人，成功助力愛芯元智半導體股份有限公司（股票代號：600.HK，簡稱 「愛芯元智」）于香港交易所主板正式挂牌上市。此次上市豐富了港股在邊緣AI推理系統芯片（「SoC」）領域的投資標的，也展現了國泰海通集團在服務半導科技企業方面的綜合實力。愛芯元智是AI推理SoC的供貨商，專注爲邊緣計算與終端設備AI應用打造高性能的感知與計算平臺，致力于構建先進的AI計算基礎設施，推動人工智能普及化。招股文件顯示，以2024年出貨量計，愛芯元智是全球第一大中高端視覺端側AI推理芯片提供商，在全球視覺端側AI推理芯片市場排名前五。愛芯元智的愛芯智眸AI-ISP是全球首個實現規模化商用的AI-ISP解决方案，成爲計算機視覺領域一大重要突破。截至2025年9月30日，愛芯元智自成立以來累計交付的SoC已突破1.65億顆。愛芯元智已獨立開發五代SoC幷實現商業化，涵蓋數十種類型，在視覺終端計算、智能汽車和邊緣AI推理應用中已實現大規模生産。此次項目發行最終定價爲每股28.2港元，全球發售共10,491.52萬股H股，基礎發行募集資金規模約29.59億港元，超額配售權完全行使後總集資額預計約34.02億港元。國際配售和香港公開發售均獲踴躍認購，其中國際配售認購倍數達6.8倍，香港公開發售認購倍數達104.82倍。此次發行獲得了來自16名基石投資者的重倉加持，包括豪威集團、雅戈爾、德賽西威及均勝電子等産業資本，以及澳大利亞養老基金NGS Super等國際專業投資方。基石投資者合計認購股份約14.43億港元，約占本次發售股份的48.76%，充分體現了市場對愛芯元智商業模式及長期發展前景的認可，也爲上市後股價穩健提供支撑。該項目的成功彰顯了國泰君安國際對人工智能芯片行業的深入理解以及服務高新技術行業的專業能力。未來，國泰海通集團將持續聚焦科技創新領域，充分發揮境內外一體化協同優勢，依托全鏈條金融服務體系，爲更多硬科技企業提供從資本運作到戰略資源整合的綜合賦能，助力其高效鏈接全球資本市場，共拓智能新時代。關於國泰君安國際國泰海通集團下屬公司國泰君安國際（股票代號：1788.HK）,是中國證券公司國際化的先行者和引領者，公司是首家通過IPO于香港聯合交易所主板上市的中資證券公司。國泰君安國際以香港爲業務基地，幷在新加坡、越南和澳門設立子公司，業務覆蓋全球主要市場，爲客戶境外資産配置提供高品質、多元化的綜合性金融服務，核心業務包括財富管理、機構投資者服務、企業融資服務、投資管理等。目前，國泰君安國際已分別獲得穆迪和標準普爾授予「Baa2」及「BBB+」長期發行人評級，MSCI ESG「A」評級, Wind ESG「A」評級及商道融綠ESG「A」評級，同時其標普全球ESG評分領先全球81%同業。公司控股股東國泰海通證券（股票代號：601211.SH/2611.HK）爲中國資本市場長期、持續、全面領先的綜合金融服務商。更多關于國泰君安國際的資訊請見:https://www.gtjai.com Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

BOSTON, Feb 11, 2026 - (ACN Newswire via SeaPRwire.com) - Bioxytran, Inc. (OTCQB: BIXT) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial evaluating ProLectin-M in subjects with laboratory-confirmed acute viral infection. The Bioxyytran Trial reports complete elimination of viral load in 100% of patients at day 7 versus placebo (p=.001).The completed Phase 2 clinical study was a randomized, double-blind, placebo-controlled, dose-optimization trial evaluating orally administered ProLectin-M in subjects with acute viral infection. The study enrolled 38 subjects, all of whom completed the study. Subjects were randomized to receive one of three ProLectin-M dose levels or a matching placebo, administered over a seven-day treatment period.Viral shedding was assessed using RT-PCR analysis of nasopharyngeal swabs collected at predefined timepoints, with viral clearance defined as non-detection of viral RNA below established PCR thresholds.The study design, endpoints, and duration confirmed Bioxytran’s earlier randomized, placebo-controlled Phase 2 trial, which demonstrated statistically significant reductions in viral load by Day 7, early clearance as soon as Day 3, and no observed viral rebounds during a 14-day post-treatment observation period. The current trial further refined dose selection of four tablets per day and evaluated the reproducibility of rapid viral clearance using the same core virologic assessment methodology.Topline Viral Clearance ResultsFollowing database lock and unblinding, treatment-wise analyses demonstrated the following outcomes:Complete elimination of viral load in 100% of treated subjects by Day 7, compared to the placebo group (p = .001)No viral rebounds observed in the treated population during the 14-day post-treatment observation periodThese results indicate rapid and sustained viral clearance in subjects treated with ProLectin-M.Viral Clearance Timing (All Subjects)Across the full study population:Day 3: 1 of 38 subjects demonstrated non-detection of viral sheddingDay 5: 16 of 38 subjects demonstrated non-detection of viral sheddingDay 7: 38 of 38 subjects demonstrated non-detection of viral sheddingThe study was designed to evaluate viral clearance kinetics and inform dose selection for future late-stage clinical development.“The study design of seven days reflects real-world applications for treating acute viral diseases, with the objective of demonstrating a statistically meaningful reduction in viral load by Day 7,” said Dr. Leslie Ajayi, Chief Medical Officer of Bioxytran. “The results demonstrate that viral clearance occurred more rapidly than anticipated, with a significant proportion of treated subjects achieving viral non-detection by Day 3 and complete clearance by Day 7.”“What continues to distinguish ProLectin-M as a broad-range antiviral drug is its novel mechanism of action,” Dr. Platt continued. “Rather than targeting viral replication inside the cell, our galectin antagonist is designed to interfere with viral entry at the cell surface. This extracellular approach may reduce reliance on immune activation and represents a fundamentally different strategy in antiviral therapy. We believe these results further support the potential of carbohydrate-based therapeutics and the emerging field of Glycovirology.”Next StepsBased on these results, Bioxytran plans to advance regulatory discussions to support late-stage clinical development and evaluate ProLectin-M across additional viral indications consistent with its broad-spectrum antiviral profile.About Bioxytran, Inc.Bioxytran, Inc. is a clinical-stage biotechnology company developing novel carbohydrate-based therapeutics targeting significant unmet medical needs in virology and other disease areas. The Company’s lead program, ProLectin-M, is being developed as a potential broad-spectrum antiviral therapeutic.For more information, please visit www.bioxytraninc.com.Investor & Media Contact:Bryan Feinberg / AmplifiXZephyr@amplifiX.net Company Contact:david.platt@bioxytraninc.com(617) 510-2539Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of applicable federal securities laws, including statements regarding the performance of the technology described herein, the interpretation of clinical trial results, regulatory plans, and future development activities. Forward-looking statements are generally identified by words such as “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements include these terms. Such statements are subject to significant risks, uncertainties, and assumptions that could cause actual results to differ materially from those expressed or implied. These risks are described in Bioxytran’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and other filings made from time to time. Bioxytran undertakes no obligation to update or revise any forward-looking statements, except as required under applicable securities laws. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com